Duchenne Care UK podcast series launched

On World Duchenne Awareness Day 2026, we are pleased to share the launch of the Duchenne Care UK podcast series, supporting the goal of delivering consistent, high-quality care across the UK. The series is based on the Duchenne Care UK Patient and Family Guides, and...

Landmark day for Duchenne as Givinostat approved for use in England

On a landmark day for the Duchenne muscular dystrophy community, we are delighted to share that the National Institute for Health and Care Excellence (NICE) has recommended the treatment givinostat (brand name Duvyzat) for use on the NHS in England. In final draft...

Solid doses first patient on Phase 3 trial

Today, Solid Biosciences announced that the first participant has been dosed in the Phase 3 Impact Duchenne clinical trial, a randomised, double-blind, placebo-controlled study evaluating SGT-003 for Duchenne. Clinical trial sites are currently active in Australia and...
Duchenne Care UK launches psychosocial guidelines

Duchenne Care UK launches psychosocial guidelines

We are delighted to share that psychosocial guidelines for Duchenne muscular dystrophy have been published by Duchenne Care UK. We are proud to be a key funder of the psychosocial programme, which is part of a wider, multi‑year national effort by Duchenne Care UK to...

Solid announces positive clinical update

Solid Biosciences has announced a positive clinical update on the SGT-003 gene therapy programme. This update includes interim safety and biomarker data from the ongoing Phase 1/2 Inspire Duchenne clinical trial. To date, 40 participants have been dosed with SGT-003...

New Duchenne treatment approved for use in Scotland

Scottish Medicines Consortium (SMC) has approved the treatment givinostat for use on the NHS in Scotland, for children aged 6+ who are still able to walk at the start of treatment. Givinostat (also known by its brand name Duvyzat) was approved for market authorisation...

Solid shares update on Inspire Duchenne clinical trial

Solid Biosciences has released an update on its Inspire Duchenne clinical trial, which is investigating the safety, tolerability and efficacy of its gene therapy candidate SGT-003. The Phase 1/2, open-label study has now dosed 23 patients, and expects to have dosed 30...

Duchenne community campaigns for givinostat

The UK’s National Institute for Health and Care Excellence (NICE) has announced it will seek further guidance on whether new treatment givinostat should be made routinely available on the NHS. NICE held its initial committee meeting to appraise the drug in July,...

Update on gene therapy Elevidys

Earlier this month the US Food and Drug Administration (FDA) requested that Sarepta Therapeutics place Elevidys clinical trials on hold, due to safety concerns. The request followed three deaths potentially related to the gene therapy products. The deaths appeared to...
DMD Care UK national meeting drives improved care

DMD Care UK national meeting drives improved care

Pictured: DRF director of operations Sheli Rodney (second from right) with fellow members of the Psychosocial Working Group: disability and education specialist Dr Janet Hoskin, DMD Care UK manager Cathy Turner, Pathfinders Neuromuscular Alliance trustee Benjamin...